Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
Date:1/29/2009

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufac
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: ... Bar-Gil as an independent director of the Company,s ... of AeroScout and served as its CEO until its ... 2012, a $240 million transaction. Recognized as the inventor ... Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions focused ...
(Date:12/13/2014)... Rockville, Maryland (PRWEB) December 12, 2014 ... Maryland, today announced its new name: Therabron Therapeutics ... words therapy and bronchioles (a type of structure in ... incorporating the company’s mission to develop novel protein therapeutics ... board of directors decided to change the name to ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/12/2014)... InSphero AG, the world’s leading provider of 3D ... data presented recently by Genentech (South San Francisco, CA) ... model system for assessment of liver toxicity. ... Analysis and Screening Technologies (FAST) Congress summarized a ... 3D InSight™ Human Liver Microtissues to 42 known ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
... ... ... ... ...
... ... ... ... ...
... leap forward in the understanding of how specific types of ... of scientists has succeeded in mapping the entire network of ... network, indicating which factors can combine to determine cell fate, ... journal Cell . Transcription factors (TFs) are proteins ...
Cached Biology Technology:LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 2LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 3LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 4LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM) 5China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 2China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 3China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 4China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 5China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 6China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 7China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 8China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 9China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 10China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 11China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 12China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 13China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 14China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 15China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 16China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 17China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 18China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 19China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 20China Cord Blood Corporation Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2010 21Researchers create atlas of transcription factor combinations 2
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... we thought that gene expression was modulated only by transcription ... could be regulated by the RISC complex (siRNA-mediated degradation via ... level is even more complex than we first imaginated... ... requirement for using a weapon or tool is finding it. ...
... five mammals living on Earth is a bat, yet their ... record and conflicting or incomplete theories about their origins and ... Riverside Biology Professor Mark Springer, has published a paper in ... molecular biology and the fossil data to fill in many ...
... breast cancer treated with radical mastectomy and adjuvant chemotherapy, ... outcomes with few long-term toxic effects, according to a ... the January 19 issue of the Journal of the ... therapy trial was designed to determine the effect on ...
Cached Biology News:A new mechanism of regulating RNA degradation 2A new mechanism of regulating RNA degradation 3Molecular biology fills gaps in knowledge of bat evolution 2Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down 2
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
Biology Products: